The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation
Open accessAbstract
BACKGROUND: We conducted a placebo-controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. METHODS: We compared azithromycin (250 mg alternate days, 12 weeks) with placebo. Primary outcome was FEV1 change at 12 weeks. RESULTS: 48 patients were randomised; (25 azithromycin, 23 placebo). It was established, post randomisation that two did not have BOS. 46 patients were analysed as intention to treat (ITT) with 33 'Completers'. ITT analysis included placebo patients treated with open-label azithromycin after study withdrawal. OUTCOME: The ITT analysis (n=46, 177 observations) estimated mean difference in FEV1 between treatments (azithromycin minus placebo) was 0.035 L, with a 95% CI of -0.112 L to 0.182 L (p=0.6). Five withdrawals, who were identified at the end of the study as having been randomised to placebo (four with rapid loss in FEV1, one withdrawn consent) had received rescue open-label azithromycin, with improvement in subsequent FEV1 at 12 weeks. Study Completers showed an estimated mean difference in FEV1 between treatment groups (azithromycin minus placebo) of 0.278 L, with 95% CI for the mean difference: 0.170 L to 0.386 L (p=<0.001). Nine of 23 ITT patients in the azithromycin group had ≥10% gain in FEV1 from baseline. No patients in the placebo group had ≥10% gain in FEV1 from baseline while on placebo (p=0.002). Seven serious adverse events, three azithromycin, four in the placebo group, were deemed unrelated to study medication. CONCLUSIONS: Azithromycin therapy improves FEV1 in patients with BOS and appears superior to placebo. This study strengthens evidence for clinical practice of initiating azithromycin therapy in BOS. TRIAL REGISTRATION NUMBER: EU-CTR, 2006-000485-36/GB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Clinical risk factors for primary graft dysfunction after lung transplantation
Diamond, J. M., Lee, J. C., Kawut, S. M., Shah, R. J., Localio, A. R., Bellamy, S. L., Lederer, D. J., Cantu, E., Kohl, B. A., Lama, V. N., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201210-1865oc · Cited by 687
Multilevel models for longitudinal data
Steele, F. (2008) · Journal of the Royal Statistical Society Series A (Statistics in Society) · doi:10.1111/j.1467-985x.2007.00509.x · Cited by 247
Cited by
Verleden, G. M., Glanville, A. R., Lease, E. D., Fisher, A. J., Calabrese, F., Corris, P. A., Ensor, C. R., Gottlieb, J., Hachem, R. R., Lama, V., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.03.009 · Cited by 952
Self-citationCurrent views on chronic rejection after lung transplantation
Verleden, G. M., Vos, R., Vanaudenaerde, B., Dupont, L., Yserbyt, J., Van Raemdonck, D., & Verleden, S. (2015) · Transplant International · doi:10.1111/tri.12579 · Cited by 92
Metadata
- Authors
- Corris, P. A., Ryan, V. A., Small, T., Lordan, J., Fisher, A. J., Meachery, G., Johnson, G., & Ward, C.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2015-02-24
- Volume
- 70
- Issue
- 5
- Pages
- 442-450
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2127410396
- Cited by
- 164
- References
- 3
- FWCI
- 17.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. https://app.cochat.ai/papers/10.1136/thoraxjnl-2014-205998
- The paper
- Corris, P. A., Ryan, V. A., Small, T., Lordan, J., Fisher, A. J., Meachery, G., Johnson, G., & Ward, C. (2015). A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation. Thorax. https://doi.org/10.1136/thoraxjnl-2014-205998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.